[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352214-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352214-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-the-lipid-metabolism-proteins-fasn-and-gpam-in-alveolar-type-ii-cells-decreases-lung-metastasis","Targeting the lipid metabolism proteins FASN and GPAM in alveolar type II cells decreases lung metastasis","","Lung metastasis seeding by cancer cells relies on lipids that are often produced by alveolar type II (AT2) cells. The study tests whether overt metastases depend on AT2 cell-derived lipids and whether AT2 cells can be therapeutically targeted. Results show that breast cancer-derived lung metastases stimulate AT2 proliferation and reprogram them into lipid feeder cells in mice and in patients. Targeting lipid metabolism proteins FASN and GPAM in AT2 cells reduces lung metastasis growth.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-the-lipid-metabolism-proteins-fasn-and-gpam-in-alveolar-type-ii-cells-decreases-lung-metastasis/352214/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-the-lipid-metabolism-proteins-fasn-and-gpam-in-alveolar-type-ii-cells-decreases-lung-metastasis/352214.png","ImageObject",300,407,{"name":42,"@type":43},"moss~","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are AT2 cells important for lung metastasis?","Question",{"text":63,"@type":64},"Cancer cells that seed in the lung require lipids often produced by alveolar type II (AT2) cells, making AT2-derived lipid supply relevant to metastatic growth.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the study find about AT2 cells near metastases?",{"text":68,"@type":64},"Breast cancer-derived lung metastases stimulate AT2 cell proliferation and reprogram them into lipid feeder cells in both mice and patients.",{"name":70,"@type":61,"acceptedAnswer":71},"How does targeting FASN and GPAM affect metastasis?",{"text":72,"@type":64},"Targeting lipid metabolism proteins FASN and GPAM in AT2 cells decreases lung metastasis growth.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352214,1790192790,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":97,"preview_urls":146},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Europe PMC unders uthManuscripts Europe M eC und Author Manuscripts  \nEurope PMC Funders Group  \nAuthor Manuscript  \nCancer Discov. Author manuscript; available in PMC 2026 June 12.  \nPublished in final edited form as:  \nCancer Discov. 2026 July 01; 16(7): 1412–1435. doi:10.1158/2159-8290.CD-25-0191 .  \nTargeting the lipid metabolism proteins FASN and GPAM in alveolar type II cells decreases lung metastasis  \nXiao-Zheng Liu 1,2 , Yulia Panina3,+ , Weigang Cai3,+ , Juan Fernández-García 1,2 , Yiming Peng-Winkler1,2,4 , Jiadong Mao5 , Alina Dahlhaus6 , Hui-Chao Zhou7,8 , Ming Liu 1,2 , Mélanie Planque 1,2,9 , Johannes Ceuppens 1,2,9 , Sebastian Igelmann1,2 , Xander Spotbeen 10 , Jakub Idkowiak10 , Jonas Dehairs 10 , Janine Theile 1,2 , Konstantinos Axarlis 11 , Kristien Borremans 12,13 , Josephine Van Cauwenberge 12,13 , Avinash Ghanate3 , Josep TarragóCelada3 , Alejandro Suárez-Bonnet 14,15 , Richard Mitter3 , Vincen Wu 16 , Paolo Inglese16 , James S. McKenzie 16 , Rory T. Steven 17 , Alex Dexter17 , Bin Yan 17 , Jean-Luc Vorng 17 , Zoltan Takats 16 , Josephine Bunch 16,17 , Ian S. Gilmore 17 , Peter Carmeliet7,8,18 , Christine Desmedt 12 , Ilaria Malanchi 11 , Johannes V. Swinnen 10 , Patricia Altea-Manzano 1,2,19 , KimAnh Lê Cao5 , Johannes Meiser6 , Mariia Yuneva3,\\# , Sarah-Maria Fendt 1,2,\\#  \n1Laboratory of Cellular Metabolism and Metabolic Regulation, VIB Center for Cancer Biology, VIB, Herestraat 49,, 3000 Leuven, Belgium.  \n2Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49,, 3000 Leuven, Belgium.  \n3The Francis Crick Institute, London, NW1 1AT, UK.  \n4 Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Dusseldorf, Dusseldorf, Germany  \n5Melbourne Integrative Genomics, School of Mathematics and Statistics, The University of Melbourne, Australia.  \nThis work is licensed under a CC BY 4.0 International license.  \n\\#corresponding authors: Mariia Yuneva, The Francis Crick Institute, London, UK, [mariia.yuneva@crick.ac.uk](mariia.yuneva@crick.ac.uk), Sarah-Maria Fendt, Bqu-KUal coLeuvenntributi,nHereg 2ntatth9rs, 3000 Leuven, Belgium, [sarah-maria.fendt@kuleuven.be](sarah-maria.fendt@kuleuven.be) .  \nContributions  \nConcept and design: X.-Z.L., Y.P., P.A-M., M.Y. and S.-M.F.  \nDevelopment of methodology: X.-Z.L., Y.P., W.C., J.F.G, H.-C.Z, Ji.Ma., A.D., V.W., R.S., J.B., Z.T., J.-L.V., I.G., K.-A.L.C., Jo.Me., J.V. S.  \nAcquisition of data (including providing animals, acquiring and managing patient samples, providing facilities, etc.): X.-Z.L., Y.P., W.C., P.A-M., M.P., X. S., J.I., J.D., Y.P.-W, M.L., S.I., J.T., K.B., J.V.C., C.D., V.W., R. S., B.Y., J.-L. V., A.D., K.A., J.C.  \nAnalysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): X.-Z.L., Y.P., W.C., J.F.G, H.-C.Z, Ji.Ma., A.D., K.A., J.C., M.P., S.I., A.G., J.T.C, A. S.-B., R.M., V. W., P.I., J. S.M., R. S., A.D., B.Y., J.-L. V., Z.T., J.B., Z.T., M.Y. and S.-M.F.  \nWriting, review and/or revision of the manuscript: X.-Z.L., Y.P., W.C., M.Y. and S.-M.F. Administrative, technical or material support (i.e. reporting or organizing data, constructing databases): X.-Z.L., J.F.G., J.T.  \nFunding acquisition: X.-Z.L., J.B., Z.T., I.G., M.Y. and S.-M.F.  \nStudy supervision: M.Y. and S.-M.F.  \nConflict of interest  \nS.-M.F. has received funding from BlackBelt Therapeutics, Auron Therapeutics and Alesta Therapeutics, was in the advisory board of Alesta Therapeutics and has consulted for Fund+ [and Droia Ventures. M.Y. is](and Droia Ventures. M.Y. is) currently employed by Calico Life Sciences. All other authors have no competing interests to disclose.  \nEurope PMC unders uthManuscripts Europe M eC und Author Manuscripts  \nLiu et al. Page 2  \n6Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, 6A, Rue Nicolas-Ernest Barblé, , 1210 Luxembourg, Luxembourg.  \n7Laborat","cbCaibw3gMoIb9UB","https://ap.wps.com/l/cbCaibw3gMoIb9UB","pdf",4052043,46,"English","# Abstract\n## Background\n## Findings\n## Therapeutic implication","[{\"question\":\"Why are AT2 cells important for lung metastasis?\",\"answer\":\"Cancer cells that seed in the lung require lipids often produced by alveolar type II (AT2) cells, making AT2-derived lipid supply relevant to metastatic growth.\"},{\"question\":\"What did the study find about AT2 cells near metastases?\",\"answer\":\"Breast cancer-derived lung metastases stimulate AT2 cell proliferation and reprogram them into lipid feeder cells in both mice and patients.\"},{\"question\":\"How does targeting FASN and GPAM affect metastasis?\",\"answer\":\"Targeting lipid metabolism proteins FASN and GPAM in AT2 cells decreases lung metastasis growth.\"}]","Targeting the lipid metabolism proteins FASN and GPAM in alveolar type II cells decreases lung metastasis | PDF",1790098332,116,[147,151,155,159,163],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/932b05f7c637b1e05f892985a79fb578.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22ed951b0cd28389d330959fbf013b3f.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/125fbcf0951f80507beda0590f639017.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0923a2f8ebed99acee25d0bb1e2b96f1.webp",980,1268,{"page_no":97,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd789ca88c1654cc6a70f78bf8e159d0.webp",979,1267]